Shares of Repligen (RGEN -40.4%) get hammered after the FDA cancels an advisory-committee...

|About: Repligen Corporation (RGEN)|By:, SA News Editor

Shares of Repligen (RGEN -40.4%) get hammered after the FDA cancels an advisory-committee meeting to review the company's new-drug application for its pancreatitis drug RG1068. The drug developer says it expects the FDA to request additional clinical-trial data.